Introduction to LLS Therapy Acceleration Program May 2019

Blood Cancers Every 3 minutes someone in the US is diagnosed with a blood cancer. More than one third of blood cancer patients do not survive five years after diagnosis. Despite improved outcomes, we need to do more!

Our Mission Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families More than $1.2 billion invested in research Unparalleled patient support and education services Advocacy to accelerate cures and access

Research Grant Programs LLS Research focuses on discovering and developing therapies to positively impact care for blood cancer patients Patient Education, Access & Advocacy Research Grant Programs Therapy Acceleration Program® Beat AML Initiative Discovery Development Commercialize

Therapy Acceleration Program (TAP) Strategic initiative established in 2007 Accelerate high-risk innovative blood cancer therapeutics Bridge the gap - especially phase I/II Academic programs Biopharma programs Meeting LLS Mission is first priority Generating ROI to further fund LLS Mission is secondary Highest risk to progress

LTherapy Acceleration Program (TAP) Supports Emerging New Therapies TAP – Progress to Date >60 projects / >$120 M invested to date 17 active programs 3 FDA-Approved Therapies Vyxeos (AML) Yescarta (DLBCL, tFL, PMBCL) Elzonris (BPDCN) Promising clinical data with CD47 mAb (DLBCL, FL)1 , anti-CD123-diphtheria toxin (BPDCN)2 duvelisib (PTCL) 3 Advani et al. 2018. NEJM. 379: 1711-1721 Pemmaraju ASH 2018, abstract 765 Horwitz et al. 2018. Blood. 131: 888-898 = new https://www.lls.org/therapy-acceleration-program

TAP Committee Endorsement LLS TAP Process Internal Diligence Expert Review TAP Committee Endorsement Contract Execution Active Project Open to funding application year round All hematological indications Therapeutics, diagnostics & supportive care Typically $2-8 M dollars (co-funding for companies) – equity or asset based Applicants fill out 1-page Inquiry Form to start the process How to apply for TAP: www.lls.org/therapy-acceleration-program

Key Criteria High Unmet Medical Need Innovative Science First-in-Class Clinical Proof of Concept Study Strong Intellectual Property Position Competent Management Team Adequate Co-Funds to Finish Proposed Studies

LLS TAP Funding is Competitive

TAP Portfolio Company Research Highlights Stemline: Approved Therapy Affimed: Forty Seven: Exciting Published Data

TAP is Bridging the Gap for Biotech

Select Active Projects in TAP Portfolio

LLS TAP Investment: Patient Testimonial Emily Dumler Emily, a 32-year-old mother of three young children, was diagnosed with non- Hodgkin lymphoma in August 2013. After a whirlwind of intense treatments over the next two years including chemotherapy, a stem cell transplant and months of hospitalization, Emily relapsed soon after each treatment. In January 2015, Emily was given a devastating prognosis – doctors said she had six months to live.  Emily received a glimmer of hope when doctors told her of a potential new treatment. In July 2015, Emily became the third patient in the world enrolled in Kite Pharma’s clinical trial for a lifesaving treatment called CAR T-cell therapy that was made possible by LLS funding. The revolutionary therapy was a success! Emily has been in remission for more than two years and today, she enjoys spending time with her family and sharing her story publicly to help others. When she learned that LLS played a major role in the funding of her treatment, she became a devoted volunteer. She raised funds through the Light The Night campaign and was the 2017 Woman of the Year in Kansas City, raising $160,000, a record for that Chapter.   The CAR T-cell immunotherapy that saved Emily was FDA approved in 2017. She hopes to continue to spread awareness and help raise funds for lifesaving treatments like the one that saved her own life.

We have one goal: A world without blood cancers Thank you We have one goal: A world without blood cancers